ISSN 0720-4299; 1439-3522;
3 papers in the library · 1 citation · publishing 1987-2026
Fortschr Neurol Psychiatr June 8, 2026 Udo Bonnet, Norbert Scherbaum, Georg Juckel et al.
[Intravenous Subnarcotic Ketamine Infusions for Treatment-Resistant Depression: Historical Development, Comparison with Esketamine Nasalspray, and Prospects].
Fortschr Neurol Psychiatr May 13, 2026 Cornelius Schüle, Anna Sobieraj, Helena Rogg 1 citation
Abstract: Esketamine is an NMDA receptor antagonist and was approved as a nasal spray in March 2019, initially in the USA and then in December 2019 in Europe, as an adjunct to antidepressant pharmacotherapy for the treatment of treatment-resistant major depression or for rapid symptom reduction in psychiatric emergency situations in patients with major depression. In addition, esketamine nasal...
Fortschr Neurol Psychiatr October 1, 1987
[Etiology and therapy of nightmares].